Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Eisai Co., Ltd.

Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage

Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.

ASCO Clinical Trials

Lilly Unlucky? Lilly Leads Big Pharma In US FDA Complete Response Letters

Clinical concerns outweigh quality issues in big pharma CRLs, a Pink Sheet analysis finds, making mirikizumab  the fourth new product candidate sponsored by Lilly to receive a CRL since 2021 – even more of an outlier: it was turned back by FDA because of manufacturing concerns.

US FDA Performance Tracker Complete Response Letters

Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More

“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.

Leadership Policy

Everything’s Coming Up Pfizer: The Biggest Of Pharma Firms Leads Industry In Pending Applications For US FDA Approval

Pfizer’s lineup of novel agents under review stands at seven, while no other big pharma has more than two novel candidates; Sanofi is tops in recent approvals since 2021, with seven novel agents cleared, but has no pending NMEs.

US FDA Performance Tracker Drug Review
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • EA Pharma Co., Ltd.
    • Eisai China Inc
    • Eisai Laboratorios
    • Eisai Mexico
    • Eisai Participacoes Ltda. (Brazil Subsidiary)
    • H3 Biomedicine
    • HI-Eisai Pharmaceutical Inc.
    • Jingyi Weixiang (Shanghai) Health Industry Development Limited
    • Liaoning TianYi Biological Pharmaceutical Co., Ltd.
    • KAN Research Institute, Inc.
    • MGI Pharma, Inc.
    • Morphotek, Inc.
    • Zycos Inc.
    • Eisai Vietnam Co., Ltd.
UsernamePublicRestriction

Register